Loading
Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
3 trials on record are attached to one of the types below rather than to Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) itself. They are grouped by the type that holds them, so someone still working out which type they have can see the whole field from here.
Query for this cancer: (TITLE:"Peripheral T-cell lymphomas" OR ABSTRACT:"Peripheral T-cell lymphomas" OR TITLE:"including cutaneous T-cell lymphoma" OR ABSTRACT:"including cutaneous T-cell lymphoma" OR TITLE:"PTCL" OR ABSTRACT:"PTCL" OR TITLE:"CTCL" OR ABSTRACT:"CTCL" OR TITLE:"Mycosis fungoides" OR ABSTRACT:"Mycosis fungoides" OR TITLE:"Anaplastic large-cell lymphoma" OR ABSTRACT:"Anaplastic large-cell lymphoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), not a curated reading list.
NPM-ALK identified by Morris et al.; ALK-positive ALCL becomes the good-prognosis PTCL.
First drugs specifically for relapsed PTCL.
Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).
Confirmatory Ro-CHOP trial negative.